Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
about
mTOR inhibitors in advanced renal cell carcinomaThe PIM kinases in hematological cancersActivity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphomaA phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma.Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolismThe treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulationCalcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: a meta-analysis.Primary sarcoma of the liver and transplantation: a case study and literature reviewLongevity, aging and rapamycin.Ribosomal protein S15A augments human osteosarcoma cell proliferation in vitro.Genistein exerts anti-leukemic effects on genetically different acute myeloid leukemia cell lines by inhibiting protein synthesis and cell proliferation while inducing apoptosis - molecular insights from an iTRAQ™ quantitative proteomics study.Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation.The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALLPreclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapyRecent developments in cancer chemotherapy oriented towards new targets.Tumor suppression by small molecule inhibitors of translation initiation.mTOR signaling: implications for cancer and anticancer therapy.Emerging drugs to replace current leaders in first-line therapy for breast cancer.Investigating mammalian target of rapamycin inhibitors for their anticancer properties.Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.Ras as a therapeutic target in hematologic malignancies.Can mTOR inhibitors reduce the risk of late kidney allograft failure?Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling.Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.Emerging metabolic targets in the therapy of hematological malignancies.Targeting the autophagy pathway using ectopic expression of Beclin 1 in combination with rapamycin in drug-resistant v-Ha-ras-transformed NIH 3T3 cells.Growth factor progranulin promotes tumorigenesis of cervical cancer via PI3K/Akt/mTOR signaling pathway.Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway.mTOR kinase inhibitors as a treatment strategy in hematological malignancies.Identification of Downstream Genes of the mTOR Pathway that Predict Recurrence and Progression in Non-Muscle Invasive High-Grade Urothelial Carcinoma of the Bladder.Alternative splicing of S6K1 promotes non-small cell lung cancer survival.Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells.Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma.Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma.Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin
P2860
Q24612127-26F471BC-3261-4268-BA31-61D29CC9F019Q28258028-7D83B00F-4443-43B8-AC63-122D6C235227Q33365126-0ADA8E15-AAC8-4200-ADD7-9B4BEF808DCFQ33404317-E3E24B7A-E65E-4368-B03E-D463BF9A4286Q33443555-9852315B-39F9-4642-B549-E7A5E681B8D8Q33738391-B636B41A-28CA-4BEC-B3E7-A24A2733A30CQ33816583-3D5ACDD6-7F30-4BEC-8A21-57255746E4ECQ34023486-6D2D826B-D4D3-43A0-BEE4-0A18A673D108Q34364731-7B555476-DB13-4567-ACA0-98A9E22F4E60Q34396541-F6411A03-8D2D-4504-857F-46FC2960BDF8Q34709618-3661D305-23F9-43A6-8CD8-35A18F570D5BQ35238980-9A3DB882-6A1E-42CF-927E-C2CD51ECF01BQ35751042-E32F3A7B-0668-497A-A2E0-5E649BB55E36Q35845541-F383EB37-8BB4-4E2B-9401-7D3CADF7E209Q35850028-7B60DAFF-C039-4072-8F30-65A080A70E5EQ35972736-70A8C9AE-4F46-4135-A9AE-8A1E6C27BAC6Q36150860-B42D21D2-B023-4C8A-A13B-9C9906B2AB8BQ36339255-1F83844B-4CE7-4E4F-9B1B-9542DC1D9AD8Q36365093-A22A2999-C7DB-491D-8222-1989582B9E16Q36580598-1A435854-6E49-4360-93F5-CE0D2A15DE31Q36600294-63E87131-5B59-42CF-B81A-89A28AAD9107Q36604270-4D6C95AB-3E44-4423-B512-85D878439EC7Q36866611-5F160E85-AF52-4BE8-8E43-A670C5BCE5E6Q36884566-2306DC2B-AD14-4D44-841F-5AE4F4F8A521Q36897348-E58DD741-305B-4ED1-BC5D-EBAEB0B7BF68Q36914970-E45A9F88-C284-411E-982A-6467E1D02442Q36973814-E3A4394E-A464-4BDC-92AE-9DFC4A4FE4EFQ37109227-CC9D4C5F-0ED5-4950-9DB2-27422F27B2F8Q37137623-AB52C459-0FD5-4EBC-BFBF-09B155BAA779Q37599431-304BF650-A575-46D4-B94E-F5F8C8038884Q37629030-E5D7E549-BDB7-4025-B476-C5991E73541AQ37775890-EF5FAEFF-EDC4-482A-9F6F-48147B1D6F1BQ37993588-A20737E5-AB3C-4DD6-A1E6-75BFAE903D13Q38431806-48468529-BFBD-4A82-BCD4-4C7FE43F0A6DQ38755663-09A13C98-2C21-4C72-8FFD-06776A4690FCQ38987856-80044024-DC47-4C37-991C-7088567FB993Q39127868-674CFC8A-D5AA-4E8C-8512-82308A5B2729Q39147866-3E189E12-C06F-4BAB-9474-0D1B344367E5Q39396713-7AAB600D-D5C8-48F7-807E-F18EE4137D5AQ39418495-EA49065E-2724-4778-BF1C-6EBD693C5183
P2860
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
@ast
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
@en
type
label
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
@ast
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
@en
prefLabel
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
@ast
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
@en
P2860
P356
P1433
P1476
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
@en
P2093
Amit Panwalkar
Francis J Giles
P2860
P304
P356
10.1002/CNCR.20026
P407
P577
2004-02-01T00:00:00Z